JP6162606B2 - アルデヒド−タグ付き免疫グロブリンポリペプチド及びその使用方法 - Google Patents

アルデヒド−タグ付き免疫グロブリンポリペプチド及びその使用方法 Download PDF

Info

Publication number
JP6162606B2
JP6162606B2 JP2013549596A JP2013549596A JP6162606B2 JP 6162606 B2 JP6162606 B2 JP 6162606B2 JP 2013549596 A JP2013549596 A JP 2013549596A JP 2013549596 A JP2013549596 A JP 2013549596A JP 6162606 B2 JP6162606 B2 JP 6162606B2
Authority
JP
Japan
Prior art keywords
polypeptide
seq
aldehyde
amino acid
constant region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013549596A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014506135A5 (enExample
JP2014506135A (ja
Inventor
エム． バーフィールド，ロビン
エム． バーフィールド，ロビン
アラン ブライデンバッハ，マーク
アラン ブライデンバッハ，マーク
ダブリュー． デハート，グレゴリー
ダブリュー． デハート，グレゴリー
ラブカ，デイビッド
Original Assignee
レッドウッド バイオサイエンス， インコーポレイテッド
レッドウッド バイオサイエンス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レッドウッド バイオサイエンス， インコーポレイテッド, レッドウッド バイオサイエンス， インコーポレイテッド filed Critical レッドウッド バイオサイエンス， インコーポレイテッド
Publication of JP2014506135A publication Critical patent/JP2014506135A/ja
Publication of JP2014506135A5 publication Critical patent/JP2014506135A5/ja
Application granted granted Critical
Publication of JP6162606B2 publication Critical patent/JP6162606B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2013549596A 2011-01-14 2012-01-13 アルデヒド−タグ付き免疫グロブリンポリペプチド及びその使用方法 Active JP6162606B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161433042P 2011-01-14 2011-01-14
US61/433,042 2011-01-14
PCT/US2012/021367 WO2012097333A2 (en) 2011-01-14 2012-01-13 Aldehyde-tagged immunoglobulin polypeptides and method of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017117430A Division JP2017200936A (ja) 2011-01-14 2017-06-15 アルデヒド−タグ付き免疫グロブリンポリペプチド及びその使用方法

Publications (3)

Publication Number Publication Date
JP2014506135A JP2014506135A (ja) 2014-03-13
JP2014506135A5 JP2014506135A5 (enExample) 2015-03-05
JP6162606B2 true JP6162606B2 (ja) 2017-07-12

Family

ID=46490926

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013549596A Active JP6162606B2 (ja) 2011-01-14 2012-01-13 アルデヒド−タグ付き免疫グロブリンポリペプチド及びその使用方法
JP2017117430A Pending JP2017200936A (ja) 2011-01-14 2017-06-15 アルデヒド−タグ付き免疫グロブリンポリペプチド及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017117430A Pending JP2017200936A (ja) 2011-01-14 2017-06-15 アルデヒド−タグ付き免疫グロブリンポリペプチド及びその使用方法

Country Status (10)

Country Link
US (2) US9540438B2 (enExample)
EP (1) EP2663647A4 (enExample)
JP (2) JP6162606B2 (enExample)
KR (1) KR20140016262A (enExample)
CN (1) CN103415621A (enExample)
AU (1) AU2012205301B2 (enExample)
BR (1) BR112013017980A2 (enExample)
CA (1) CA2824143C (enExample)
RU (1) RU2606016C2 (enExample)
WO (1) WO2012097333A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9238878B2 (en) 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
JP6162606B2 (ja) 2011-01-14 2017-07-12 レッドウッド バイオサイエンス， インコーポレイテッド アルデヒド−タグ付き免疫グロブリンポリペプチド及びその使用方法
WO2014074218A1 (en) * 2012-11-12 2014-05-15 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
KR102486180B1 (ko) 2014-06-06 2023-01-11 레드우드 바이오사이언스 인코포레이티드 항-her2 항체-메이탄신 컨쥬게이트 및 이것의 사용 방법
KR102794936B1 (ko) * 2015-02-05 2025-04-14 알.피.쉐러 테크놀러지즈 엘엘씨 활성화된 포르밀글리신-생성 효소 및 그것의 생산 및 사용 방법
KR20250008141A (ko) 2015-08-07 2025-01-14 이미지냅 인코포레이티드 분자를 표적화하기 위한 항원 결합 구조체
ES2908470T3 (es) * 2015-11-09 2022-04-29 Scherer Technologies Llc R P Conjugados de anticuerpo anti-CD22-maitansina y métodos de uso de los mismos
US11168131B2 (en) 2015-11-10 2021-11-09 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
CN109071634A (zh) * 2016-04-26 2018-12-21 R.P.谢勒技术有限责任公司 抗体偶联物及其制备和使用方法
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
ES2994374T3 (en) 2017-01-18 2025-01-23 Visterra Inc Antibody molecule-drug conjugates and uses thereof
WO2018147960A1 (en) * 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
WO2018169953A1 (en) * 2017-03-17 2018-09-20 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
TW201920249A (zh) 2017-09-07 2019-06-01 美商信號生物製藥公司 具有結合位點之t細胞調節多聚體多肽及其使用方法
EP3688007B1 (en) 2017-09-27 2024-07-31 The University of York Bioconjugation of polypeptides
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
CN108610415B (zh) * 2018-05-15 2025-08-29 康元大工生物技术(大连)有限公司 一种抗体复合物的制备方法
US11377488B2 (en) 2018-07-03 2022-07-05 Catalent Pharma Solutions, Llc Multifunctional protein molecules comprising decorin and use thereof
WO2020081493A1 (en) 2018-10-16 2020-04-23 Molecular Templates, Inc. Pd-l1 binding proteins
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
WO2021055816A1 (en) 2019-09-18 2021-03-25 Molecular Templates, Inc. Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds
KR20220079576A (ko) 2019-10-04 2022-06-13 알.피.쉐러 테크놀러지즈 엘엘씨 항-cd25 항체-메이탄신 접합체 및 이의 사용 방법
EP4126064A1 (en) 2020-04-03 2023-02-08 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
WO2021211930A1 (en) * 2020-04-17 2021-10-21 Shire Human Genetic Therapies, Inc. Forms and compositions of inhibitors of plasma kallikrein
US12030888B2 (en) 2021-02-24 2024-07-09 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
CA3172530A1 (en) 2021-02-25 2022-09-01 Spencer PARK Ror1 targeting chimeric antigen receptor
WO2022197945A1 (en) 2021-03-17 2022-09-22 Molecular Templates, Inc. Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens
US20240376509A1 (en) * 2021-05-27 2024-11-14 R.P. Scherer Technologies, Llc Methods of Controlling Cleavage of Formylglycine-Containing Polypeptides
CA3252263A1 (en) 2022-02-09 2025-07-07 National Institutes Of Biomedical Innovation, Health And Nutrition ANTIBODY OR FRAGMENT OF IT BINDING TO FCRL1
CN116284419B (zh) * 2023-02-07 2024-10-11 深圳市先康达生命科学有限公司 靶向人gucy2c蛋白的单克隆抗体及其应用

Family Cites Families (250)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342832A (en) 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
JPS5630925A (en) 1979-08-21 1981-03-28 Sumitomo Chem Co Ltd Purification of human growth hormone
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US6710169B2 (en) 1987-10-02 2004-03-23 Genentech, Inc. Adheson variants
US4952394A (en) 1987-11-23 1990-08-28 Bristol-Myers Company Drug-monoclonal antibody conjugates
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
GB8824869D0 (en) 1988-10-24 1988-11-30 Stevenson G T Synthetic antibody
US5681566A (en) 1988-10-24 1997-10-28 3I Research Exploitation Limited Antibody conjugates with two or more covalently linked FC regions
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CS89491A3 (en) 1990-04-09 1992-01-15 Chugai Pharmaceutical Co Ltd Hybrid calcitonin
RU2145233C1 (ru) * 1990-07-02 2000-02-10 Дзе Аризона Борд оф Риджентс Неупорядоченная библиотека пептидов, способ ее получения и способ идентификации пептида, синтезированного твердофазным синтезом
DE69231467T2 (de) 1991-05-10 2001-01-25 Genentech, Inc. Auswählen von agonisten und antagonisten von liganden
US6329509B1 (en) 1991-08-14 2001-12-11 Genentech, Inc. Anti-IgE antibodies
SK279641B6 (sk) 1991-12-20 1999-01-11 Novo Nordisk A/S Stabilizovaný farmaceutický prípravok obsahujúci r
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
CA2076465C (en) 1992-03-25 2002-11-26 Ravi V. J. Chari Cell binding agent conjugates of analogues and derivatives of cc-1065
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5484892A (en) 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
AU3272695A (en) 1994-08-12 1996-03-07 Immunomedics Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5698672A (en) 1995-04-04 1997-12-16 Zymogenetics, Inc. Synthetic calcitonin mimetics
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
JP3871713B2 (ja) 1995-05-10 2007-01-24 協和醗酵工業株式会社 新規毒素複合体
ATE247488T1 (de) 1995-10-13 2003-09-15 Us Gov Health & Human Serv Immunotoxin enthaltend ein disulfid- stabilisiertes antikörperfragment
ATE267610T1 (de) 1996-03-20 2004-06-15 Immunomedics Inc Glykosylierte igg antikörper
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6653104B2 (en) 1996-10-17 2003-11-25 Immunomedics, Inc. Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
PT1629849E (pt) 1997-01-07 2013-07-09 Amylin Pharmaceuticals Llc Composições farmacêuticas que compreendem exendinas e seus agonistas
US6548644B1 (en) 1997-03-10 2003-04-15 Immunex Corporation Site protected protein modification
DE69838979T2 (de) 1997-03-20 2008-12-24 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
JP2002510193A (ja) 1997-03-31 2002-04-02 イーライ・リリー・アンド・カンパニー グルカゴン様ペプチド−１類似体
CN1269805A (zh) 1997-07-14 2000-10-11 博尔德生物技术公司 生长激素和相关蛋白的衍生物
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6803451B2 (en) 1998-09-23 2004-10-12 Zymogenetics, Inc. Cytokine receptor zalpha11 polypeptides
US6576744B1 (en) 1998-09-23 2003-06-10 Zymogenetics, Inc. Cytokine receptor zalpha11
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US7425541B2 (en) 1998-12-11 2008-09-16 Medarex, Inc. Enzyme-cleavable prodrug compounds
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
US6395226B1 (en) 1999-04-06 2002-05-28 Medtronic, Inc. Alkoxysilane/alkysilane copolymer coating of medical devices
DE19926475A1 (de) 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Träger-Pharmaka-Konjugate
CA2385528C (en) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6824780B1 (en) 1999-10-29 2004-11-30 Genentech, Inc. Anti-tumor antibody compositions and methods of use
CA2393369A1 (en) 1999-12-03 2001-06-07 Zymogenetics, Inc. Human cytokine receptor
CA2400034A1 (en) 2000-02-17 2001-08-23 Incyte Genomics, Inc. Human kinases
US6570040B2 (en) 2000-03-16 2003-05-27 The Regents Of The University Of California Chemoselective ligation
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
DE60125543T2 (de) 2000-04-05 2007-10-04 Zymogenetics, Inc., Seattle Löslicher zytokinrezeptor zalpha11
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
AU2001273983A1 (en) 2000-05-02 2001-11-12 Lutz F. Tietze Novel prodrugs von 6-hydroxy-2,3-dihydro-1h-indoles, 5-hydroxy-1,2-dihydro-3h-pyrrolo(3,2-e)indoles and 5-hydroxy-1,2-dihydro-3h-benzo(e)indoles as well as of 6-hydroxy-1,2,3,4-tetrahydro-benzo(f)quinoline derivatives for use in selective cancer therapy
AU2001264946A1 (en) 2000-05-24 2001-12-03 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
US7214663B2 (en) 2000-06-14 2007-05-08 Medarex, Inc. Tripeptide prodrug compounds
AU2001266853B2 (en) 2000-06-14 2005-02-17 Medarex, Inc. Prodrug compounds with an oligopeptide having an isoleucine residue
EP2177616B1 (en) 2000-08-08 2012-02-29 ZymoGenetics, Inc. Soluble zcytor 11 cytokine receptors
US7402556B2 (en) 2000-08-24 2008-07-22 Medarex, Inc. Prodrugs activated by plasmin and their use in cancer chemotherapy
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
US20020128448A1 (en) * 2000-10-20 2002-09-12 Idec Pharmaceuticals Corporation Variant IgG3 Rituxan and therapeutic use thereof
JP2004516826A (ja) 2000-11-07 2004-06-10 ザイモジェネティクス，インコーポレイティド ヒト腫瘍壊死因子受容体
GB0029154D0 (en) 2000-11-30 2001-01-17 Lee Helen Signal enhancement with multiple labelled-antibodies
ES2311560T3 (es) 2000-12-07 2009-02-16 Eli Lilly And Company Proteinas de fusion glp-1.
WO2002070655A2 (en) 2001-03-02 2002-09-12 Zymogenetics, Inc. Mouse cytokine receptor
EP1383492A4 (en) 2001-03-23 2008-12-24 Napro Biotherapeutics Inc MOLECULAR CONJUGATES FOR USE IN CANCER THERAPY
CA2439961A1 (en) 2001-03-27 2002-10-03 Zymogenetics, Inc. Human cytokine receptor
IL158418A0 (en) 2001-04-19 2004-05-12 Scripps Research Inst In vivo incorporation of unnatural amino acids
US7256257B2 (en) 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6608196B2 (en) 2001-05-03 2003-08-19 Galileo Pharmaceuticals, Inc. Process for solid supported synthesis of pyruvate-derived compounds
US20030013656A1 (en) 2001-05-03 2003-01-16 Bing Wang Pyruvate derivatives
US20030103985A1 (en) 2001-05-18 2003-06-05 Boehringer Ingelheim International Gmbh Cytotoxic CD44 antibody immunoconjugates
US6978243B2 (en) 2001-05-22 2005-12-20 International Flavors & Fragrances Inc. Method for the analysis of sensory perception
EA010594B1 (ru) 2001-05-24 2008-10-30 Займодженетикс, Инк. Слитые белки taci-иммуноглобулина
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US7087600B2 (en) 2001-05-31 2006-08-08 Medarex, Inc. Peptidyl prodrugs and linkers and stabilizers useful therefor
JP4619651B2 (ja) 2001-06-01 2011-01-26 コーネル・リサーチ・ファンデーション・インコーポレイテッド 前立腺特異的膜抗原に対する修飾抗体およびその使用
US7803915B2 (en) 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US20030109682A1 (en) 2001-09-07 2003-06-12 Daniel Santi Maytansines and maytansine conjugates
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
CA2461351C (en) 2001-09-26 2014-08-05 Ira H. Pastan Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells
US6864069B2 (en) 2001-10-05 2005-03-08 Bayer Pharmaceuticals Corporation Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
EP2042196B1 (en) 2001-10-10 2016-07-13 ratiopharm GmbH Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF)
KR100988949B1 (ko) 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
US20030171285A1 (en) 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
GB0130947D0 (en) 2001-12-24 2002-02-13 Lee Helen Improved sample preparation for the detection of infectious agents
DE60334364D1 (de) 2002-02-21 2010-11-11 Univ California Behandlungsverfahren unter verwendung von anti-cd22-antikörpern
US20090042291A1 (en) 2002-03-01 2009-02-12 Xencor, Inc. Optimized Fc variants
US20100311954A1 (en) 2002-03-01 2010-12-09 Xencor, Inc. Optimized Proteins that Target Ep-CAM
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
US20070148171A1 (en) 2002-09-27 2007-06-28 Xencor, Inc. Optimized anti-CD30 antibodies
US20080219974A1 (en) 2002-03-01 2008-09-11 Bernett Matthew J Optimized antibodies that target hm1.24
US20080199471A1 (en) 2002-03-01 2008-08-21 Bernett Matthew J Optimized cd40 antibodies and methods of using the same
US20080152649A1 (en) 2002-03-01 2008-06-26 Xencor, Inc. Optimized igf-1r antibodies and methods of using the same
US20090162382A1 (en) 2002-03-01 2009-06-25 Bernett Matthew J Optimized ca9 antibodies and methods of using the same
US20080206242A1 (en) 2002-03-01 2008-08-28 Xencor, Inc. Method of treatment of th2-mediated conditions using optimized anti-cd30 antibodies
US20080260731A1 (en) 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
US20080254027A1 (en) 2002-03-01 2008-10-16 Bernett Matthew J Optimized CD5 antibodies and methods of using the same
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
BR0308090A (pt) 2002-03-01 2006-04-11 Univ Tulane conjugados de agentes citotóxicos ou terapêuticos e peptìdios biologicamente ativos
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
JP4524181B2 (ja) 2002-05-30 2010-08-11 マクロジェニクス，インコーポレーテッド Ｃｄ１６ａ結合タンパク質および免疫障害治療のための使用
EP1551453A4 (en) 2002-06-17 2007-04-25 Us Gov Health & Human Serv SPECIFICITY GRAFTING OF A MICE RESPONSE TO A HUMAN FRAME
ES2544527T3 (es) 2002-07-31 2015-09-01 Seattle Genetics, Inc. Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa
ES2361739T3 (es) 2002-08-16 2011-06-21 Immunogen, Inc. Reticulantes con elevada reactividad y solubilidad y su uso en la preparación de conjugados para el suministro dirigido de fármacos de molécula pequeña.
US7189811B2 (en) 2002-09-06 2007-03-13 National Institute Of Immunology Process for solubilization of recombinant proteins expressed as inclusion body
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
MXPA05003978A (es) 2002-10-16 2005-06-22 Scripps Research Inst Sintesis de glicoproteinas.
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
EP1588166A4 (en) 2003-01-09 2007-06-27 Macrogenics Inc VECTOR SYSTEM WITH DOUBLE EXPRESSION FOR EXPRESSING ANTIBODIES IN BACTERIAL AND MAMMAL CELLS
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
CN101444621B (zh) 2003-02-11 2013-11-20 夏尔人类遗传性治疗公司 使用甲酰-甘氨酸生成酶(fge)对多种硫酸酯酶缺乏症和其它病症进行诊断和治疗
DK1594542T3 (da) 2003-02-20 2010-10-11 Seattle Genetics Inc Anti-CD70 antistof-lægemiddelkonjugater og deres anvendelse ved behandling af cancer
US20070275460A1 (en) 2003-03-03 2007-11-29 Xencor.Inc. Fc Variants With Optimized Fc Receptor Binding Properties
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
WO2004082640A2 (en) 2003-03-19 2004-09-30 New Century Pharmaceuticals, Inc. Human serum albumin conjugates with therapeutic compounds
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
WO2004108885A2 (en) 2003-05-06 2004-12-16 Syntonix Pharmaceuticals, Inc. Fc chimeric proteins with anti-hiv drugs
ES2333598T5 (es) 2003-05-06 2013-09-04 Biogen Idec Hemophilia Inc Proteinas quimericas del factor de coagulacion fc para tratar la hemofilia.
US7374762B2 (en) 2003-05-14 2008-05-20 Immunogen, Inc. Drug conjugate composition
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
JP4629047B2 (ja) 2003-06-12 2011-02-09 イーライ リリー アンド カンパニー Ｇｌｐ−１アナログ複合タンパク質
BRPI0411475A (pt) 2003-06-18 2006-07-25 Scripps Research Inst adições de código genético de aminoácido reativo não natural
US7700097B2 (en) 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
KR101672664B1 (ko) * 2003-07-21 2016-11-04 이뮤노젠 아이엔씨 인간화된 항체 또는 그의 항원결정기 결합절편
US6943234B2 (en) 2003-07-30 2005-09-13 Zymogenetics, Inc. Pichia methanolica secretory signal
US20060134105A1 (en) 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
US20070148170A1 (en) 2005-10-03 2007-06-28 Desjarlais John R Fc Variants With Optimized Fc Receptor Binding Properties
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
AR047720A1 (es) 2003-09-30 2006-02-15 Bio Sidus S A Un proceso para la obtencion de mamiferos transgenicos que produzcan proteinas exogenas en leche y los mamiferos producidos por dicho proceso
SG176455A1 (en) 2003-10-09 2011-12-29 Ambrx Inc Polymer derivatives
EP3434275A1 (en) 2003-11-06 2019-01-30 Seattle Genetics, Inc. Assay for cancer cells based on the use of auristatin conjugates with antibodies
WO2005047337A1 (en) 2003-11-13 2005-05-26 Hanmi Pharmaceutical Co., Ltd. A pharmaceutical composition comprising an immunoglobulin fc region as a carrier
ES2343965T3 (es) 2003-11-25 2010-08-13 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Anticuerpos anti-cd22 e inmunocongujados mutados.
EP1701979A2 (en) 2003-12-03 2006-09-20 Xencor, Inc. Optimized antibodies that target the epidermal growth factor receptor
JP2007512846A (ja) 2003-12-04 2007-05-24 ゼンコー・インコーポレイテッド 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
CA2550050A1 (en) 2003-12-18 2005-06-30 Novo Nordisk A/S Novel glp-1 analogues linked to albumin-like agents
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
AU2005319099B2 (en) 2004-02-02 2010-09-16 Ambrx, Inc. Modified human growth hormone
CN103755800B (zh) 2004-02-02 2016-02-24 Ambrx公司 经修饰的人类生长激素多肽与其用途
US7422696B2 (en) 2004-02-20 2008-09-09 Northwestern University Multicomponent nanorods
EP1718667B1 (en) 2004-02-23 2013-01-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
CA2558399C (en) 2004-03-02 2015-05-19 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
WO2005092925A2 (en) 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
US20050260711A1 (en) 2004-03-30 2005-11-24 Deepshikha Datta Modulating pH-sensitive binding using non-natural amino acids
WO2005101017A1 (en) 2004-04-07 2005-10-27 Genentech, Inc. Mass spectrometry of antibody conjugates
JP2007536932A (ja) 2004-05-10 2007-12-20 マクロジェニクス，インコーポレーテッド ヒト化ＦｃγＲＩＩＢ特異的抗体とその利用法
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
US7517903B2 (en) 2004-05-19 2009-04-14 Medarex, Inc. Cytotoxic compounds and conjugates
MXPA06014065A (es) 2004-06-01 2007-01-31 Genentech Inc Conjugados de droga-anticuerpo y metodos.
CN102532321B (zh) 2004-06-18 2018-10-12 Ambrx公司 新颖抗原结合多肽和其用途
US7638299B2 (en) 2004-07-21 2009-12-29 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
US7126393B2 (en) 2004-08-20 2006-10-24 Micron Technology, Inc. Delay circuit with reset-based forward path static delay
CA2579142A1 (en) 2004-09-13 2006-03-23 Macrogenics, Inc. Humanized antibodies against west nile virus and therapeutic and prophylactic uses thereof
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
US7442778B2 (en) * 2004-09-24 2008-10-28 Amgen Inc. Modified Fc molecules
CN101061137A (zh) 2004-11-09 2007-10-24 Usv有限公司 用于纯化人生长激素的新方法
WO2007024249A2 (en) 2004-11-10 2007-03-01 Macrogenics, Inc. Engineering fc antibody regions to confer effector function
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US20070135620A1 (en) 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
BRPI0517837A (pt) 2004-11-12 2008-10-21 Xencor Inc variantes fc com ligação alterada a fcrn
US7255012B2 (en) 2004-12-01 2007-08-14 Rosemount Inc. Process fluid flow device with variable orifice
AU2005323106B2 (en) 2004-12-22 2010-07-29 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
US7385028B2 (en) 2004-12-22 2008-06-10 Ambrx, Inc Derivatization of non-natural amino acids and polypeptides
NZ555425A (en) 2004-12-22 2010-04-30 Ambrx Inc Compositions of aminoacyl-tRNA synthetase and uses thereof
KR101224781B1 (ko) 2004-12-22 2013-01-21 암브룩스, 인코포레이티드 비천연적으로 코딩된 아미노산을 포함하는 인간 성장호르몬의 조제물
ES2343746T3 (es) 2005-01-07 2010-08-09 Diadexus, Inc. Composiciones de anticuerpo ovr110 y metodos de uso.
JP5165387B2 (ja) 2005-02-11 2013-03-21 イムノゲン インコーポレーティッド 安定な薬物複合体を調製するための方法
US7466406B2 (en) 2005-03-14 2008-12-16 Northwestern University Analyte detection using nanowires produced by on-wire lithography
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
ES2707152T3 (es) 2005-04-15 2019-04-02 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
WO2006133088A2 (en) 2005-06-03 2006-12-14 Ambrx, Inc. Improved human interferon molecules and their uses
WO2006132969A2 (en) 2005-06-03 2006-12-14 Ambrx, Inc. Incorporation of non-naturally encoded amino acids into proteins
JP2007037018A (ja) 2005-07-29 2007-02-08 Nec Electronics Corp スイッチ回路
HUE029465T2 (en) 2005-08-10 2017-02-28 Macrogenics Inc Identification and engineering of antibodies with variant Fc regions and methods of using same
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
CA2618878C (en) 2005-08-18 2016-06-28 Ambrx, Inc. Compositions of trna and uses thereof
WO2007048127A2 (en) 2005-10-20 2007-04-26 The Scripps Research Institute Fc labeling for immunostaining and immunotargeting
CN101365679B (zh) 2005-10-26 2012-11-14 梅达莱克斯公司 制备cc-1065类似物的方法和化合物
CN103965300A (zh) 2005-11-02 2014-08-06 Ambrx公司 生物合成多肽融合抑制剂
SI1954710T1 (sl) 2005-11-08 2011-08-31 Ambrx Inc Pospeĺ evala za modifikacijo nenaravnih aminokislin in nenaravnih peptidov aminokislin
EP1951890A4 (en) 2005-11-16 2009-06-24 Ambrx Inc PROCESSES AND COMPOSITIONS WITH NON-NATURAL AMINO ACIDS
KR101423898B1 (ko) 2005-12-14 2014-07-28 암브룩스, 인코포레이티드 비-천연 아미노산 및 폴리펩티드를 함유하는 조성물, 비-천연 아미노산 및 폴리펩티드를 포함하는 방법, 및 비-천연 아미노산 및 폴리펩티드의 용도
EP1978989A4 (en) 2005-12-30 2009-03-18 Ambrx Inc AMINO ACIDS AND NON-NATURAL POLYPEPTIDES, COMPOSITIONS CONTAINING THEM, METHODS INVOLVING THEM AND USES THEREOF
CN101384711A (zh) 2006-01-19 2009-03-11 Ambrx公司 具有经调节的免疫原性的非天然氨基酸多肽
US20070198996A1 (en) 2006-02-09 2007-08-23 Ziep Software Inc. System and method for driving peripheral devices
CA2638819A1 (en) 2006-02-10 2008-04-03 Zymogenetics, Inc. Soluble il-17rcx4 and methods of using in inflammation
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
EP1998799B8 (en) 2006-03-06 2014-03-05 Medlmmune, LLC Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP1999470A4 (en) 2006-03-10 2009-08-19 Macrogenics Inc IDENTIFICATION AND GENETIC MODIFICATION OF ANTIBODIES WITH HEAVY CHAINS OF VARIANTS AND METHODS OF USE THEREOF
CA2660592C (en) 2006-05-26 2016-07-12 Macrogenics, Inc. Humanized fc.gamma.riib-specific antibodies and methods of use thereof
WO2007140371A2 (en) 2006-05-30 2007-12-06 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
CN100388056C (zh) 2006-06-02 2008-05-14 上海微电子装备有限公司 一种投影物镜光学系统
AU2007281876B2 (en) 2006-06-26 2013-09-05 Macrogenics, Inc. FcgammaRIIB-specific antibodies and methods of use thereof
WO2008011446A2 (en) 2006-07-18 2008-01-24 Centocor, Inc. Human glp-1 mimetibodies, compositions, methods and uses
PT2064333E (pt) 2006-09-08 2014-06-09 Ambrx Inc Supressor híbrido arnt para células de vertebrados
WO2008030558A2 (en) 2006-09-08 2008-03-13 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
ES2457527T3 (es) 2006-09-08 2014-04-28 Ambrx, Inc. ARNt Supresor hibrido en células de vertebrados
US20100093082A1 (en) 2006-09-08 2010-04-15 Ambrx, Inc. Site Specific Incorporation of Non-Natural Amino Acids by Vertebrate Cells
US7985783B2 (en) * 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
US20080112961A1 (en) 2006-10-09 2008-05-15 Macrogenics, Inc. Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
US7476555B2 (en) 2006-11-15 2009-01-13 Airdio Wireless Inc. Method of chip manufacturing
EP2097097B1 (en) 2006-12-01 2018-05-30 E. R. Squibb & Sons, L.L.C. Antibodies, in particular human antibodies, that bind cd22 and uses thereof
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
WO2008077079A1 (en) 2006-12-18 2008-06-26 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
JP4467557B2 (ja) 2006-12-25 2010-05-26 富士通株式会社 光スイッチング方法及び光スイッチ
AU2007341997A1 (en) 2006-12-28 2008-07-10 Ambrx, Inc. Phenazine and quinoxaline substituted amino acids and polypeptides
JP5163642B2 (ja) * 2007-03-29 2013-03-13 コニカミノルタホールディングス株式会社 有機エレクトロルミネセンス素子
KR101476472B1 (ko) 2007-03-30 2015-01-05 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
US20080244222A1 (en) 2007-03-30 2008-10-02 Intel Corporation Many-core processing using virtual processors
KR20100019467A (ko) 2007-05-02 2010-02-18 암브룩스, 인코포레이티드 변형된 인터페론 베타 폴리펩티드 및 그의 용도
TW200902554A (en) 2007-05-08 2009-01-16 Genentech Inc Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates
AU2008260498B2 (en) 2007-05-30 2012-11-29 Xencor, Inc. Methods and compositions for inhibiting CD32b expressing cells
US8318508B2 (en) 2007-06-20 2012-11-27 Northwestern University Patterning with compositions comprising lipid
WO2009046407A2 (en) 2007-10-04 2009-04-09 Zymogenetics, Inc. B7 FAMILY MEMBER zB7H6 AND RELATED COMPOSITIONS AND METHODS
WO2009117030A2 (en) 2007-12-19 2009-09-24 Macrogenics, Inc. Improved compositions for the prevention and treatment of smallpox
US7722865B2 (en) 2008-01-18 2010-05-25 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
US8729232B2 (en) * 2008-03-27 2014-05-20 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
US8591889B2 (en) 2008-04-04 2013-11-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human monoclonal antibodies specific for CD22
AU2009262199B2 (en) * 2008-06-27 2012-08-09 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
EP2358860A1 (en) 2008-11-21 2011-08-24 Corning Incorporated Spaced projection substrates and devices for cell culture
US9238878B2 (en) * 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
JP6162606B2 (ja) 2011-01-14 2017-07-12 レッドウッド バイオサイエンス， インコーポレイテッド アルデヒド−タグ付き免疫グロブリンポリペプチド及びその使用方法
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
CN105744935B (zh) 2013-11-27 2022-09-30 雷德伍德生物科技股份有限公司 肼基-吡咯并化合物及用于生成缀合物的方法
KR102486180B1 (ko) 2014-06-06 2023-01-11 레드우드 바이오사이언스 인코포레이티드 항-her2 항체-메이탄신 컨쥬게이트 및 이것의 사용 방법

Also Published As

Publication number Publication date
RU2606016C2 (ru) 2017-01-10
EP2663647A4 (en) 2015-08-19
AU2012205301A1 (en) 2013-07-18
JP2017200936A (ja) 2017-11-09
WO2012097333A2 (en) 2012-07-19
WO2012097333A3 (en) 2012-09-07
US20170166639A1 (en) 2017-06-15
RU2013137868A (ru) 2015-02-20
US20120183566A1 (en) 2012-07-19
EP2663647A2 (en) 2013-11-20
US9540438B2 (en) 2017-01-10
US10183998B2 (en) 2019-01-22
AU2012205301B2 (en) 2017-01-05
BR112013017980A2 (pt) 2017-06-27
CA2824143C (en) 2018-12-18
CN103415621A (zh) 2013-11-27
CA2824143A1 (en) 2012-07-19
JP2014506135A (ja) 2014-03-13
KR20140016262A (ko) 2014-02-07

Similar Documents

Publication Publication Date Title
US10183998B2 (en) Aldehyde-tagged immunoglobulin polypeptides and methods of use thereof
US12215080B2 (en) Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
US11788066B2 (en) Antibody conjugates and methods of making and using the same
US20250381290A1 (en) Antibody Conjugates and Methods of Making and Using the Same
WO2026039627A1 (en) Antibody conjugates and methods of making and using the same
CN118043328A (zh) 对nectin-4特异性的抗体和抗体缀合物及其使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170519

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170615

R150 Certificate of patent or registration of utility model

Ref document number: 6162606

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250